Intravesikale Radioimmuntherapie des Carcinoma in situ der Harnblase nach BCG-Versagen

[1]  R. Senekowitsch-Schmidtke,et al.  Fractionated intravesical radioimmunotherapy with 213Bi-anti-EGFR-MAb is effective without toxic side-effects in a nude mouse model of advanced human bladder carcinoma , 2015, Cancer biology & therapy.

[2]  M. Schwaiger,et al.  Intravesical α-Radioimmunotherapy with 213Bi-Anti-EGFR-mAb Defeats Human Bladder Carcinoma in Xenografted Nude Mice , 2009, Journal of Nuclear Medicine.

[3]  K. Schmid,et al.  [Urinary tract tumor registry]. , 2007, Der Urologe. Ausg. A.

[4]  H. Rübben,et al.  Prognosefaktoren des Harnblasenkarzinoms , 2007, Der Urologe.

[5]  F. Kraeber-Bodéré,et al.  Current status and perspectives in alpha radioimmunotherapy. , 2006, The quarterly journal of nuclear medicine and molecular imaging : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR), [and] Section of the Society of....

[6]  D. Zaak,et al.  Standards und Perspektiven in der Diagnostik und Therapie des Harnblasenkarzinoms , 2006, Der Urologe.

[7]  R. Hautmann,et al.  Long-term results of standard procedures in urology: the ileal neobladder , 2006, World Journal of Urology.

[8]  J. Dunst,et al.  Radiochemotherapy after transurethral resection for high-risk T1 bladder cancer: an alternative to intravesical therapy or early cystectomy? , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  P. Gontero*,et al.  Actual experience and future development of gemcitabine in superficial bladder cancer. , 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

[10]  S. Sataa,et al.  Contemporary management of stage T1 transitional cell carcinoma of the bladder. , 2005, La Tunisie medicale.

[11]  S. Fosså,et al.  Expression of the epidermal growth factor receptor family in normal and malignant urothelium , 2005, BJU international.

[12]  O. Couturier,et al.  Cancer radioimmunotherapy with alpha-emitting nuclides , 2005, European Journal of Nuclear Medicine and Molecular Imaging.

[13]  C. Dinney,et al.  Novel approaches with targeted therapies in bladder cancer. Therapy of bladder cancer by blockade of the epidermal growth factor receptor family. , 2003, Critical reviews in oncology/hematology.

[14]  P. Malmström,et al.  Alternating mitomycin C and BCG instillations versus BCG alone in treatment of carcinoma in situ of the urinary bladder: a nordic study. , 2003, European urology.

[15]  T. Sun,et al.  Overexpression of epidermal growth factor receptor in urothelium elicits urothelial hyperplasia and promotes bladder tumor growth. , 2002, Cancer research.

[16]  J. Montie,et al.  Bladder cancer clinical guidelines panel summary report on the management of nonmuscle invasive bladder cancer (stages Ta, T1 and TIS). The American Urological Association. , 1999, The Journal of urology.

[17]  R. Knuechel,et al.  [Standards and perspectives in diagnosis and therapy of bladder carcinoma]. , 2006, Der Urologe. Ausg. A.

[18]  R. Gascoyne,et al.  Favorable outcome of primary mediastinal large B-cell lymphoma in a single institution: the British Columbia experience. , 2006, Annals of oncology : official journal of the European Society for Medical Oncology.